These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 26901343

  • 1. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    Trojano M.
    Eur Neurol; 2016; 75 Suppl 1():4-8. PubMed ID: 26901343
    [Abstract] [Full Text] [Related]

  • 2. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
    Patti F.
    Eur Neurol; 2016; 75 Suppl 1():9-12. PubMed ID: 26901344
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
    Fernández Ó.
    Eur Neurol; 2016; 75 Suppl 1():1-3. PubMed ID: 26901342
    [Abstract] [Full Text] [Related]

  • 5. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R.
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    Trojano M, Vila C.
    Eur Neurol; 2015 Oct; 74(3-4):178-85. PubMed ID: 26571097
    [Abstract] [Full Text] [Related]

  • 7. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L.
    Eur Neurol; 2016 Oct; 75(5-6):236-43. PubMed ID: 27160412
    [Abstract] [Full Text] [Related]

  • 8. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J.
    Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O.
    Eur Neurol; 2014 Jun; 72 Suppl 1():9-11. PubMed ID: 25278117
    [Abstract] [Full Text] [Related]

  • 11. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
    Trojano M, Celius EG, Donzé C, Izquierdo G, Patti F, Pöhlau D.
    Eur Neurol; 2014 Jun; 72 Suppl 1():15-9. PubMed ID: 25278119
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.
    Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C.
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Advances in the management of MS spasticity: recent observational studies.
    Fernández O.
    Eur Neurol; 2014 Feb; 72 Suppl 1():12-4. PubMed ID: 25278118
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.